Saxagliptin (trade name: Onglyza) has been approved in Germany since October 2009 for the treatment of type 2 diabetes in adults who cannot lower blood sugar levels enough through exercise and diet alone. This drug can be combined with other blood-sugar-lowering medications such as metformin, sulfonylurea or insulin. It can be used as a single drug too, if metformin is not well tolerated.
Diabetes is a metabolic disease that affects many parts of the body. In type 2 diabetes, the pancreas still produces enough insulin at first, but the body’s cells gradually lose the ability to absorb and use the insulin. If blood sugar levels cannot be lowered enough through a change in diet and exercise habits, blood-sugar-lowering medication is used.
The aim of this treatment in type 2 diabetes is to avoid strong fluctuations in blood sugar levels and the effects of high and low blood sugar. A further goal of this treatment is to prevent long-term complications that may arise if blood sugar levels are too high.
Saxagliptin is taken once a day in tablet form at a dose of 5 mg. If saxagliptin is combined with sulfonylurea or insulin, their doses may have to be adjusted to prevent hypoglycemia.
Type 2 diabetes can be treated with a number of different medicines, either as monotherapy or in combination with each other. These medicines include metformin, sulfonylurea and insulin.
The Institute for Quality and Efficiency in Health Care (IQWiG, Germany) last looked into whether saxagliptin offers advantages or disadvantages when compared with the standard treatments in 2016.
However, the manufacturer did not provide any suitable data with which to do the assessment. This is also true of the SAVOR-TIMI 53 study.
This information summarizes the main results of reviews produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The reviews were commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the reviews and the hearings received, the G-BA passed a resolution on the added benefit of saxagliptin (Onglyza).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Saxagliptin: Benefit assessment according to § 35a Social Code Book V; Dossier assessment; Commission A13-01. Juner 27, 2013. (IQWiG reports; Volume 174).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Saxagliptin (new area of application): Benefit assessment according to § 35a Social Code Book V; Dossier assessment; Commission A13-32. December 2, 2013. (IQWiG reports; Volume 197).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Saxagliptin (type 2 diabetes) – Benefit assessment according to §35a Social Code Book V; Dossier assessment; Commission A16-42. September 29, 2016. (IQWiG reports; Volume 442).
IQWiG health information is written with the aim of helping
people understand the advantages and disadvantages of the main treatment options and health
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.